Senior Research Officer, Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute
Sarah Diepstraten completed her PhD at La Trobe University in molecular genetics and developmental biology. She is now a post-doctoral scientist at the Walter and Eliza Hall Institute. Her research focuses on understanding how blood cancers become resistant to therapy and how this can be overcome. She develops genetic engineering approaches (CRISPR) to find genes involved in drug resistance. She has also taught in undergraduate science courses at La Trobe University and Melbourne University, and is passionate about science education.
How does the drug abemaciclib treat breast cancer?
May 08, 2024 11:03 am UTC| Health Business
The anti-cancer drug abemaciclib (also known as Vernezio) has this month been added to the Australian Pharmaceutical Benefits Scheme (PBS) to treat certain types of breast cancer. This significantly reduces the cost of...
South Africa’s plan to move away from coal: 8 steps to make it succeed
Germany lowers voting age to 16 for the European elections
IceCube researchers detect a rare type of energetic neutrino sent from powerful astronomical objects